The focus of the industry on human living organisms and the strict standards it enforces are unique to business leaders. These characteristics make the industry an ideal incubator for innovation. They have resulted in major breakthroughs biofuels, crop yields, and life-saving pharmaceuticals.

Start-up biotech companies have many choices when it comes to revenue generation strategies, with most opting for a technology-based partnership or an out-licensing and asset creation strategy. Technology partnering offers faster revenues with less risk of financial loss while an asset creation and out-licensing strategy will yield more lucrative returns if https://genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ it is successful. A growing number of biotechs at the research stage use a hybrid approach that combines both strategies.

People who opt for a product-centric strategy can reap commercial success when they are able to get their pipelines to the right place, and attract a big pharmaceutical partner or a financier with deep pockets. It can be a costly proposition but balancing opportunistic approaches to leveraging outside assets with the right research-based decisions regarding homegrown projects is key.

The “platform” model is an alternative option to generate revenue. It is less expensive than product-oriented development but also involves significant risk. In this model biotechs own and develops its platform technology before joining with major pharma companies to create a portfolio of drug discovery projects that focus on specific disease areas (i.e. disease the x gene within biology y). This is the model Advinus Therapeutics and a few others have adopted.